Ready-to-use AAV9 particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV Retrograde particles produced from pAAV-Syn-ChR2(H134R)-GFP (#58880). In addition to the viral particles, you will also receive purified pAAV-Syn-ChR2(H134R)-GFP plasmid DNA. Humanized channelrhodopsin H134R mutant fused to GFP, under the control of the Synapsin promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV5 particles produced from pAAV-hSynapsin1-FLEx-axon-GCaMP6s (#112010). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-FLEx-axon-GCaMP6s plasmid DNA. Synapsin-driven, cre-dependent axon targeted GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV9 particles produced from pAAV-CAG-dLight1.3b (#125560). In addition to the viral particles, you will also receive purified pAAV-CAG-dLight1.3b plasmid DNA. CAG-driven expression of dLight1.3b dopamine sensor. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV Retrograde particles produced from AAV-CAG-hChR2-H134R-tdTomato (#28017). In addition to the viral particles, you will also receive purified AAV-CAG-hChR2-H134R-tdTomato plasmid DNA. Humanized channelrhodopsin H134R mutant fused to tdTomato, under the control of the CAG promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from AiP14035: pAAV-AiE0452h_3xC2-minBG-CoChR-EGFP-WPRE3-BGHpA (Alias: CN4035) (#214853). In addition to the viral particles, you will also receive purified AiP14035: pAAV-AiE0452h_3xC2-minBG-CoChR-EGFP-WPRE3-BGHpA (Alias: CN4035) plasmid DNA. minBG-driven expression of CoChR-EGFP striatal indirect pathway medium spiny neurons (D2 MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO mScarlet (#131002). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO mScarlet plasmid DNA. EF1a-driven, Cre-dependent mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from AiP11390-pAAV-DLX2.0-minBG-SYFP2-WPRE3-BGHpA (Alias: CN1390) (#163505). In addition to the viral particles, you will also receive purified AiP11390-pAAV-DLX2.0-minBG-SYFP2-WPRE3-BGHpA (Alias: CN1390) plasmid DNA. AAV vector for strong and rapid SYFP2 expression in forebrain GABAergic interneurons. The enhancer core sequence has 100% sequence conservation between mouse and human. Developed especially for rapid viral labeling in human and NHP organotypic brain slice culture. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from CAG-NLS-GFP (#104061). In addition to the viral particles, you will also receive purified CAG-NLS-GFP plasmid DNA. CAG-driven NLS-GFP expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from AAV-FLEX-Arch-GFP (#22222). In addition to the viral particles, you will also receive purified AAV-FLEX-Arch-GFP plasmid DNA. CAG-driven cre-dependent Arch-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.